

EXPERIENCES CHALLENGE COCCIDIOSIS VACCINATION BROILERS Terms and Conditions

1. Introduction.

- 1.1. Coccidiosis remains a significant challenge for poultry producers. While chemoprophylaxis is being more and more contested due to the appearance of resistances and the One Health Approach, the use of vaccination strategies is becoming an increasing trend in broiler production. However, not all coccidiosis vaccines are based on the same technology. The attenuated by preciousness method, based on genetic selection, was developed in order to achieve attenuated strains without any risk of virulence. In addition, these strains are producing less asexual replications, with a lower damage of the gut cells and providing the necessary immune response against coccidiosis. This is why, the attenuated by preciousness vaccines, is the preferable method of coccidiosis vaccination in several countries.

2. Object.

- 2.1. The objective of this scientific Challenge is to showcase the performance of attenuated by precociousness vaccines against coccidiosis, administered through spray or *in ovo* injection, on commercial broiler farms by means of field data (hereinafter the "Data Trial").
- 2.2. The top 3 Data Trials will be selected for submission as abstracts at the 2027 AAAP Annual Meeting¹. The author/s of each selected trial will be rewarded with the opportunity to attend the event, which will take place in July 2027 in the city of Forth Worth, Texas (USA), as presenters (either through a poster or an oral presentation).

3. Participation

- 3.1. The opening of this scientific Challenge will be announced at HIPRA's LinkedIn profile and/or <https://hipra.com/en/experiences-challenge-coccidiosis-vaccination-broilers>.
- 3.2. The Challenge is open to avian veterinary surgeons, practitioners and/or other professionals (independent or working for a company, veterinary practice or producer) eligible to participate according to the applicable law.
- 3.3. Any questions in connection with the Challenge shall be addressed to corporate.poultry@hipra.com indicating as subject CHALLENGE COCCIDIOSIS VACCINATION BROILERS. The Jury members, their relatives, or HIPRA's employees cannot participate in the Challenge.
- 3.4. The Participation in this Challenge implies acceptance of these Terms and Conditions.
- 3.5. In order to participate in this scientific Challenge, the participants should submit the Data Trial as defined in point 4 below to the following e-mail address global.poultry@hipra.com. Data Trial can be submitted until 23:59 on the **15th December 2026**.
- 3.6. The Jury's decision will be communicated to all participants on or before **20th January 2027** by means of publication at <https://www.hipra.com/>.
- 3.7. Failure to meet the Terms and Conditions of this scientific Challenge or failure to complete the mandatory information will result in the impossibility of participating in the Challenge.

4. Data Trial

- 4.1. Each Data Trial submitted during this scientific Challenge should have one main author, from now on, the Author and must describe the Author's own and original experience.

¹ <https://www.aaap.info/future-annual-meetings>

- 4.2. Any and all costs of conducting the trials will be covered by the Author.
- 4.3. The Author declares to be the author of the Data Trial and to be entitled to assign its exploitation rights.
- 4.4. The Author declares that the trials have been conducted considering the ethical postulates and guidelines on animal protection.
- 4.5. The submitted Data Trials should include the following information:
 - 4.5.1. Description of the objective/s of the trial: 1) comparison of the attenuated by precociousness vaccines with other coccidiosis vaccines (non-attenuated or attenuated by other methods) or the use of coccidiostats; and/ or 2) evaluation of the attenuated by precociousness coccidiosis vaccine performance;
 - 4.5.2. Description of the materials and methods (number of birds, vaccination programme used, laboratorial analyses performed);
 - 4.5.3. Description of the results including:
 - 4.5.3.1. Productive parameters (mortality, etc.) of minimum three continuous cycles where the coccidiosis vaccine has been administered;
 - 4.5.3.2. Results of the laboratorial analyses, such as oocysts per gram (in case they have been performed).

5. Jury

- 5.1. The Jury will be made up of the following HIPRA professionals: Marc Pagès (R&D Department), Martina Dardi (Marketing Department) and an external coccidiosis expert.
- 5.2. The members of the Jury will elect the President from amongst themselves who, in the unlikely event of a tie, will have a deciding vote.
- 5.3. There is no right of appeal against the decision of the Jury.

6. Acknowledgements

- 6.1. The main reward of this scientific Challenge is acknowledgement of the top 3 positive experiences administering attenuated coccidiosis vaccines.
- 6.2. In order to not only acknowledge the Authors of 3 top Data Trial but also assist in their professional development, they will also be awarded with the attendance as presenters / authors (either through a poster or an oral presentation) at the 2027 AAAP Annual Meeting that will be celebrated on July 2027 in the city of Forth Worth, Texas (USA) or any other meeting/congress of HIPRA's choice should they were issues with the Author's participation. All reasonable travel expenses, including 2026 AAAP registration, will be covered by HIPRA.
- 6.3. In consideration of the aforesaid, the Authors of the top 3 Data Trials grant to HIPRA exploitations rights to the Data Trials and the associated image rights as indicated in the point 7.1 hereinbelow.
- 6.4. The award cannot be divided, nor be transferred to a different participant.
- 6.5. In the event that the selected Author cannot be contacted, the Jury will select the next one, and so on.
- 6.6. The value of the compensation is subject to applicable tax regulations.

7. Intellectual Property and Confidentiality

- 7.1. In consideration of the Acknowledgements as agreed in point 6 hereinabove, the Authors of the top 3 Data Trials assign exclusively to HIPRA any and all exploitation rights to Data Trials that they may hold and their respective copyrights. Likewise, the Authors authorize HIPRA to use their images and name in any and all photographs, images, videos, and performances or sound recordings which are taken from them in connection with the Challenge, always in relation to HIPRA's area of business. The images shall not be used contrary to the Authors' right to honor,

reputation or good taste. HIPRA shall be able to edit, modify, publish, broadcast or combine the images with other images, text, graphics, film, audio, audio-visual works at any time and by means of any media. These assignments and authorizations have neither geographic nor time limits.

8. Processing of personal data

- 8.1. The personal data provided by the participants will be handled strictly in accordance with the regulations in force regarding personal data protection.
- 8.2. The data collected from the participants can be stored in a file owned by HIPRA and may be used to keep participants informed on the latest HIPRA's products and services in the field of veterinary medicine and animal health.
- 8.3. HIPRA's privacy policy is available at <https://www.hipra.com/en/privacy-policy>

9. Final provisions

- 9.1. HIPRA reserves the right to modify, for justified reasons, these Terms and Conditions, as well as the composition of the Jury.
- 9.2. All information concerning this scientific Challenge can be accessed at <https://hipra.com/en/experiences-challenge-coccidiosis-vaccination-broilers>.
- 9.3. Any questions in connection with the Challenge shall be addressed to global.poultry@hipra.com.

February 3rd, 2026